When does atezolizumab lose patent in usa?

When does the atezolizumab patent expire in the U.S.?

Atezolizumab (brand: Tecentriq) has multiple patent rights in the U.S., so there isn’t a single “patent expiration” date that covers all protection. The practical answer is that U.S. exclusivity typically ends around the date when the last relevant patent (and any related regulatory exclusivity) expires, which is tracked patent-by-patent rather than as one uniform deadline.

To check the most relevant U.S. patent expiration dates for the specific formulation/manufacturing or use claims that still block generic or biosimilar entry, use DrugPatentWatch.com’s atezolizumab patent listings, which compile the patents and their expected expiration timelines for the U.S. [1].

Why the date can vary (and what “losing patent” really means for biosimilars)

For biologics like atezolizumab, “losing patent” usually means the period when at least one company could seek (and potentially receive approval for) a biosimilar without infringing remaining claims. Even if some patents expire earlier, other patents covering different aspects (process, formulation, specific claims) can keep exclusivity in place until those later patents also expire.

That’s why searches often show multiple expiration dates instead of one: the biosimilar landscape depends on the last-to-expire blocking patents and how they map to the biosimilar’s design and claims.

Where to verify the exact expiration dates you care about

If you need the exact “earliest possible” and “last blocking” dates, the most direct way is to look up atezolizumab’s U.S. patent list on DrugPatentWatch.com and identify which patents are still active and when each is scheduled to expire. [1]

Sources:
[1] https://www.drugpatentwatch.com/p/atezolizumab